

S 867

Medicare Prescription Drug Program Integrity and Transparency Act of 2013

Congress: 113 (2013–2015, Ended)

Chamber: Senate

Policy Area: Health

Introduced: May 6, 2013

Current Status: Read twice and referred to the Committee on Finance.

Latest Action: Read twice and referred to the Committee on Finance. (May 6, 2013)

Official Text: https://www.congress.gov/bill/113th-congress/senate-bill/867

Sponsor

Name: Sen. Pryor, Mark L. [D-AR]

Party: Democratic • State: AR • Chamber: Senate

Cosponsors (5 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Boozman, John [R-AR]	R · AR		May 6, 2013
Sen. Moran, Jerry [R-KS]	R · KS		May 6, 2013
Sen. Wicker, Roger F. [R-MS]	R · MS		May 6, 2013
Sen. Cochran, Thad [R-MS]	R · MS		May 8, 2013
Sen. Johnson, Tim [D-SD]	D · SD		May 8, 2013

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	May 6, 2013

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
113 HR 4437	Related bill	Apr 11, 2014: Referred to the Subcommittee on Health.

Medicare Prescription Drug Program Integrity and Transparency Act of 2013 - Amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act to require each contract entered into with a prescription drug plan (PDP) sponsor with respect to a PDP the sponsor offers to prohibit the PDP from entering into a contract with any pharmacy benefits manager (PBM) to manage the prescription drug coverage provided under such plan, or to control the costs of the prescription drug coverage under it, unless the manager satisfies specified PBM audit and disclosure requirements.

Requires a PBM to provide: (1) a particular aggregate average reimbursement rate for generics or a maximum average discount off of an accepted pharmaceutical pricing benchmark for multi-source generics as a whole ("generic effective rate"), and (2) a process for the generic effective rate to be appealed.

Revises requirements for contracts with PDP sponsors to require that the PDP sponsor or a subcontractor of the sponsor disclose to a pharmacy, at the time when a contract is offered and at least once every seven days, the methodology and actual per unit reimbursement amount for each covered drug for each contracted pharmacy.

Actions Timeline

- **May 6, 2013:** Introduced in Senate
- **May 6, 2013:** Read twice and referred to the Committee on Finance.